Skin Injuries Following Layperson Application of Chemical Peel Products.

Allison Lardieri, Melissa Reyes, Karen E Konkel, Ida-Lina Diak, Lynda McCulley

Abstract readReview

In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Allison LardieriAll authors are with the Division of Pharmacovigilance, Office of Surveillance and Epidemiology at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland.

Melissa ReyesAll authors are with the Division of Pharmacovigilance, Office of Surveillance and Epidemiology at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland.

Karen E KonkelAll authors are with the Division of Pharmacovigilance, Office of Surveillance and Epidemiology at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland.

Ida-Lina DiakAll authors are with the Division of Pharmacovigilance, Office of Surveillance and Epidemiology at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland.

Lynda McCulleyAll authors are with the Division of Pharmacovigilance, Office of Surveillance and Epidemiology at the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe sought to characterize skin injuries following layperson application of chemical peel products (CPPs).

methodsCases of skin injuries following layperson application of CPPs from August 31, 2018 through August 31, 2023 were retrieved from the United States Food and Drug Administration (FDA) Adverse Event Reporting System, the Human Foods Complaint System, the literature, and Amazon.com consumer product reviews with images.

resultsWe identified 18 skin injuries following layperson application of CPPs, including several cases using products labeled with concentrations typically used by healthcare professionals. Injuries involved burns with associated wounds, pain, swelling, and scars. Consequences included disfiguring scarring, reduced mobility, and need for emergency department, dermatologic, or surgical care. Analysis of Amazon.com demonstrated that CPPs are sold under many names with numerous therapeutic claims, list a variety of concentrated agents, and have thousands of reviews. LIMITATIONS: Limitations include underreporting of adverse events to the FDA and incomplete clinical information. With consumer product reviews, there was potential bias and poor replicability due to the dynamic nature of the Amazon website.

conclusionLaypersons who apply CPPs of any strength without guidance from licensed and trained healthcare professionals may experience skin injury and long-term sequelae. Dermatologists are positioned to advise against application of CPPs without professional supervision.

Indexed as

Chemical burnchemical peeldermatologyself-medicationskin injurytopical productunapproved product

Identifiers

PMID41446714

PMCPMC12724979

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.